Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel beta coronavirus. SARS-CoV-2 uses spike glycoprotein to interact with host angiotensin-converting enzyme 2 (ACE2) and ensure cell recognition. High infectivity of SARS-CoV-2 rai...

Full description

Bibliographic Details
Main Authors: Masaud Shah, Bilal Ahmad, Sangdun Choi, Hyun Goo Woo
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Computational and Structural Biotechnology Journal
Subjects:
COVID-19
mAb
SARS-CoV-2
Spike protein
Therapeutic peptides
Online Access:http://www.sciencedirect.com/science/article/pii/S2001037020304694

Internet

http://www.sciencedirect.com/science/article/pii/S2001037020304694

Similar Items